A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of azithromycin administered once a week in the
prevention of disseminated Mycobacterium avium complex (MAC) in severely immunocompromised
HIV-infected patients with a CD4 count < 100 cells/mm3.